Sector News

Parexel seeking $4B sale: WSJ

May 9, 2017
Life sciences

Not a week seems to go by without a CRO sale rumor: Chiltern, INC Research and PPD (which in fact was recapitalized last week) are two of the most recent, and now the Wall Street Journal is adding Parexel to that list.

The financial news service is reporting anonymous “people familiar with the matter” as saying the CRO is up for sale; it currently has a market cap of around $3.8 billion, but a premium could see it worth over $4 billion.

The 20,000-employee Boston-area company saw its share price tick up by more than 7% yesterday on the rumor.

“The company has drawn interest from activist investors, including Corvex Management LP, which has built a sizable stake in Parexel,” according to a person familiar with the matter talking to WSJ. Parexel is not commenting on the story.

Parexel has itself been on the M&A trail, and back in February acquired contract medical affairs services provider The Medical Affairs Company (TMAC), bolstering its outsourced healthcare specialist offering.

The deal, financial terms of which were not disclosed, saw the CRO gain access to Georgia-based TMAC and its outsourced medical affairs services to biopharma and the medical device industries.

But the company, one of the major CRO players, has also had its problems, and last year its chief financial officer and senior vice president, Ingo Bank, resigned from the company just days before its fourth-quarter results were released.

Then, a few weeks later, it delayed its 10-K filing as it looked into “misappropriation of corporate funds” by an employee.

In its SEC 12b-25 filing, the company said it found out that one of its employees, who works “in one of the company’s international operations,” had apparently been misusing its money.

Back in October 2015, Parexel narrowed its outlook for fiscal 2016, reducing its revenue target by about 2% at midpoint to around $2.14 billion amid sliding profits.

The CRO had been in the process of shedding around 850 jobs during that year, with the goal of saving between $20 million and $30 million a year starting from 2016.

Covance, itself bought by LabCorp in 2015 and now subject to cuts, tried to buy Parexel 18 years ago for $671 million, but the deal was eventually called off.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.